rs4562997 — SMAD3

Second intronic enhancer variant in SMAD3 that modulates TGF-beta effector signaling in regulatory T cells, influencing susceptibility to autoimmune and inflammatory conditions including IBD

See your personal result for SMAD3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SMAD3 rs4562997 — The Second TGF-beta Enhancer Switch

SMAD3 is the central intracellular signal transducer of TGF-beta (transforming growth factor-beta)11 TGF-beta (transforming growth factor-beta)
A pleiotropic cytokine that governs immune tolerance, Treg differentiation, and mucosal homeostasis; when TGF-beta binds its receptor, SMAD2 and SMAD3 are phosphorylated and translocate to the nucleus to regulate target genes, the master pathway governing regulatory T cell (Treg) differentiation and immune tolerance. In immune cells, SMAD3 is required for Foxp3 expression — the transcription factor that defines Tregs — and for restraining both Th2 (allergic) and Th17 (autoimmune mucosal) lineages. rs4562997 is a second intronic enhancer variant in SMAD3, located at chromosome 15q22.33 (position 67,165,814 on GRCh38), roughly 15.5 kilobases downstream from the first confirmed enhancer variant, rs17293632. Together they constitute two independently validated regulatory control points for SMAD3 expression.

The Mechanism

Functional luciferase reporter assays22 Functional luciferase reporter assays
Reporter assays in which the variant sequence drives expression of a luminescent protein, enabling direct quantification of allele-specific transcriptional activity in thyroid cancer cell lines (TPC-1 and BCPAP) confirmed that both rs4562997 and rs17293632 regulate SMAD3 transcription through allele-specific enhancer elements located within SMAD3 introns. The two enhancers act independently — each drives SMAD3 expression based on the allele present at that position — meaning the combined haplotype state of both variants determines the net SMAD3 expression level in cells where these enhancers are active. Both alleles at rs4562997 produce measurably different transcriptional outputs (p<0.01 to p<0.001 in reporter assays), confirming the variant is not a passenger polymorphism but a true functional regulatory element.

The Evidence

The SMAD3 locus appears in Crohn's disease GWAS by Franke et al. 201033 Crohn's disease GWAS by Franke et al. 2010 in a meta-analysis of six datasets (6,333 cases, 15,056 controls discovery phase; 29,720 replication), confirming SMAD3 among 71 established Crohn's susceptibility genes.

For the partner variant rs17293632, O'Donnell et al. 201944 O'Donnell et al. 2019 in a North American Crohn's cohort of 1,495 patients found that SMAD3 was among eight susceptibility variants associated with accelerated progression to abdominal surgery (P<0.05), suggesting SMAD3 functional status influences disease course, not just susceptibility. The Brylak et al. 2025 pediatric IBD study55 Brylak et al. 2025 pediatric IBD study in 286 Polish children observed SMAD3 genotype-associated differences in corticosteroid requirements in Crohn's disease. rs4562997 is the second functional variant contributing to the same regulatory program, and individuals carrying risk alleles at both enhancer positions are expected to have more substantially reduced SMAD3 expression than either variant alone would predict. Direct clinical outcome data specific to rs4562997 are not yet available independently of rs17293632.

Practical Actions

The A allele at rs4562997 marks reduced SMAD3 enhancer activity at this second regulatory element. As with rs17293632, the clinical consequence is not deterministic — most carriers remain disease-free — but the allele reduces SMAD3-mediated immune tolerance capacity, lowering the threshold for mucosal inflammation. The gut microbiome is the most tractable environmental modifier: short-chain fatty acids (SCFAs) from fiber fermentation, particularly butyrate, reinforce Foxp3+ Treg differentiation through SMAD3-dependent pathways and can partially compensate for reduced baseline SMAD3 enhancer activity. Fiber diversity (30+ plant species per week) predicts microbiome richness and SCFA production more reliably than total fiber quantity alone.

Carriers of the AA genotype who also carry the rs17293632 T allele face compounding SMAD3 expression reduction across two independent enhancers — the combined haplotype effect is likely greater than either variant alone, warranting more proactive gut health monitoring.

Interactions

rs4562997 and rs17293632 are both confirmed allele-specific SMAD3 enhancers located within the same gene, ~15.5 kb apart. Their combined haplotype state determines net SMAD3 expression in enhancer-active tissues. Carriers of risk alleles at both positions (A at rs4562997, T at rs17293632) may have more substantially impaired TGF-beta–SMAD3 signaling than either variant predicts individually. The SMAD3 pathway also intersects with IL-10 (rs1800795) signaling — IL-10 cooperates with TGF-beta for mucosal tolerance — so risk alleles in both pathways compound gut mucosal vulnerability.

Genotype Interpretations

What each possible genotype means for this variant.

GG Intact Second Enhancer Normal

Common genotype — both SMAD3 enhancer elements at standard activity, population-baseline immune tolerance capacity

You carry two copies of the common G allele at rs4562997. Both copies of this second intronic SMAD3 enhancer are at their standard transcriptional activity level. Combined with your status at the partner variant rs17293632, your overall SMAD3 regulatory program runs at population-baseline capacity. Your genetic risk for SMAD3-mediated immune conditions at this locus is at the population average. Roughly 42% of people globally carry this GG genotype.

AG Partial Second Enhancer Reduction Intermediate

One copy of the A risk allele — modestly reduced SMAD3 enhancer activity at this second regulatory element, with mild additional immune tolerance impairment

rs4562997 acts as an allele-specific enhancer element within an intron of SMAD3, confirmed by luciferase reporter assays (Wang et al. 2018, PMID 29300379). One copy of the A allele reduces enhancer-driven SMAD3 transcription from that chromosome, mildly lowering the total cellular SMAD3 output relative to the GG state. SMAD3 is required for Foxp3 induction (master Treg transcription factor) downstream of TGF-beta receptor signaling. For heterozygous carriers, the impairment is partial — one functional G-allele copy continues to drive normal enhancer activity — and disease risk attributable to this single variant alone is modest.

AA Dual Second Enhancer Reduction High Risk

Two copies of the A risk allele — both SMAD3 enhancer copies at reduced activity, with elevated immune tolerance impairment and IBD susceptibility

Homozygous AA individuals carry the lower-activity SMAD3 enhancer allele on both chromosomes at this second regulatory element. Both copies of the SMAD3 gene rely on the reduced-activity A allele enhancer at this position. Combined with the first confirmed enhancer at rs17293632, an individual who is AA at rs4562997 and TT at rs17293632 carries compounding impairments at two independent SMAD3 regulatory sites.